Loading clinical trials...
Loading clinical trials...
A Phase II Study of Intratumoral Administration of L19IL2/L19TNF in Non-melanoma Skin Cancer Patients With Presence of Injectable Lesions
Conditions
Interventions
L19IL2 +L19TNF
Locations
11
Germany
Universitätsklinikum Augsburg
Augsburg, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany
University Hospital Carl Gustav Carus
Dresden, Germany
Universitätsklinikum Essen (AöR)
Essen, Germany
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, Germany
University Medical Center Schleswig Holstein
Kiel, Germany
Start Date
September 2, 2020
Primary Completion Date
September 1, 2024
Completion Date
September 1, 2024
Last Updated
October 10, 2023
NCT05955924
NCT01455363
NCT00218868
NCT02436408
NCT02310503
NCT04124796
Lead Sponsor
Philogen S.p.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions